COST-EFFECTIVENESS AND OUTCOMES GUIDELINES -- AS WELL AS DRUG PRICING -- WOULD BE OVERSEEN BY DrugPAC UNDER STARK BILL; OUTCOMES DATA TO BE COLLECTED BY AHCPR
Executive Summary
The development of guidelines on drug cost-effectiveness and relative outcomes would be overseen by the same entity that evaluates the pricing of drugs under the alternative health care reform proposal developed by Rep. Stark (D-Calif.) that is now being marked up by his House Ways & Means/Health Subcommittee.